SCHEDULE: Intracoastal Capital Takes 4.99% Stake in Outlook Therapeutics

Intracoastal Capital LLC and its principals have reported a 4.99% beneficial ownership stake in Outlook Therapeutics following a recent securities purchase agreement.

Summary

• Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher have disclosed a combined 4.99% stake in the company.
• The position was established following a Securities Purchase Agreement (SPA) executed on April 22, 2026.
• The reporting group holds 5,137,613 common shares and warrants to purchase additional shares.
• Total beneficial ownership is currently capped at 4.99% due to specific blocker provisions in the warrant agreements.
• Without these blockers and pending necessary approvals, the group's potential ownership could reach approximately 13,589,226 shares.
• The transaction involved the issuance of 16,129,033 shares of Common Stock at the closing of the SPA.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive as it confirms institutional backing and the successful closing of a capital raise, though the warrant structure implies significant future dilution.

Positives

• Secured significant institutional investment from Intracoastal Capital LLC.
• The investment follows a capital-raising event that provides the company with immediate liquidity.
• The reporting persons have certified that the shares were acquired for passive investment purposes rather than to influence corporate control.

Negatives

• Ownership is intentionally capped at 4.99% to avoid regulatory thresholds, which may limit the investor's immediate financial commitment.
• The structure of the investment includes significant warrant coverage, which implies future equity dilution for existing shareholders.
• Full exercise of warrants is contingent upon future shareholder approval and corporate charter amendments.

Risks

• Dilution risk from the potential exercise of Intracoastal Warrant 1 (6,451,613 shares) and Warrant 2 (up to 2,000,000 shares).
• Regulatory risk regarding the necessity of obtaining stockholder approval for the issuance of shares under the warrants.
• Operational risk as the company must successfully amend its certificate of incorporation to increase authorized shares to accommodate the new securities.

Future Outlook

Future warrant exercises are contingent upon obtaining stockholder approval to increase authorized shares and the effective date of an amendment to the Issuer's certificate of incorporation.

Management Comments

• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that clinical-stage biopharmaceutical companies like Outlook Therapeutics frequently rely on private placements and warrant-heavy structures to fund ongoing R&D and regulatory pathways, often attracting specialized healthcare investors like Intracoastal Capital.

Comparison to Industry Standards

• The 4.99% blocker is a standard feature in private investment in public equity (PIPE) transactions to avoid triggering Section 16 insider reporting requirements.
• The use of warrants as incentives in a Securities Purchase Agreement is common practice for Nasdaq-listed biotech firms when raising capital under clinical development pressure.
• The requirement for a charter amendment to increase authorized shares is a typical hurdle for micro-cap companies that have exhausted their initial equity pools.

Corporate Governance

Stakeholder Impact

• Existing shareholders face immediate dilution from the 16.1 million shares issued in the SPA.
• Potential for further dilution upon warrant exercise following shareholder approval.
• Increased liquidity for the company to pursue its strategic objectives.

Next Steps

• Seek stockholder approval for the issuance of shares related to Intracoastal Warrant 1.
• Amend the Issuer's certificate of incorporation to increase authorized shares of Common Stock.

Key Dates

Recommendation

While the institutional investment provides necessary capital, the heavy warrant overhang and the requirement for a charter amendment to increase authorized shares suggest a period of consolidation and potential volatility for the stock.

Keywords

Outlook Therapeutics, Intracoastal Capital LLC, Schedule 13G, Securities Purchase Agreement, Biotechnology, Common Stock, Warrants, Passive Investment